a b s t r a c t
The present data are related to the article entitled "Insights into ligand stimulation effects on gastro-intestinal stromal tumors signaling" (C. Bahlawane, M. Schmitz, E. Letellier, K. Arumugam, N. Nicot, P.V. Nazarov, S. Haan, 2016) [1] . Constitutive and ligandderived signaling pathways mediated by KIT and PDGFRA mutated proteins found in gastrointestinal stromal tumors (GIST) were compared. Expression of mutant proteins was induced by doxycycline in an isogenic background (Hek293 cells). Kit was identified by FACS at the cell surface and found to be quickly degraded or internalized upon SCF stimulation for both Kit Wild type and Kit mutant counterparts. Investigation of the main activated pathways in GIST unraveled a new feature specific for oncogenic KIT mutants, namely their ability to be further activated by Kit ligand, the stem cell factor (scf). We were also able to identify the MAPK pathway as the most prominent target for a common inhibition of PDGFRA and KIT oncogenic signaling. Western blotting and microarray analysis were applied to analyze the capacities of the mutant to induce an effective STATs response. Among all Kit mutants, only Kit Ex11 deletion mutant was able to elicit an effective STATs response whereas all PDGFRA were able to do so.
& Value of the data Expression of different mutant proteins (Kit and PDGFRA) in an isogenic background to allow a direct comparison of their signalling capacities, without the complex patient specific-background. The constructs and/or the Hek293 cell lines, could be used for further molecular characterization, protein-protein interaction experiments or protein localization studies. Identified mutations in GIST could easily be investigated by insertion of the newly discovered mutation in the WT constructs by site-directed mutagenesis. Plasmids are available upon request.
Identification of a new feature specific to Kit mutants: their ability to be further stimulated by their natural ligand, in addition to their constitutive activation derived from the mutations observed in GIST.
A new MEK inhibitor (PD0325901) was identified to be efficient in inhibiting GIST cell proliferation in the nanomolar range.
Data
The data presented here derived mainly from western blot analysis for the quantification of signaling pathways activated by KIT and PDGFRA mutants, from micro-array analysis for quantification of changes in gene expression levels induced by the different mutations and from flow cytometry analysis for the detection of KIT at the cell surface. Doxycycline induces Kit expression by a factor 100 in all cell lines and comparable mRNA expression levels were observed for all mutants (Fig. 1a) . However, some differences in the protein expression levels were observed between the different constructs (Fig. 1b) .
The ratio of surface (Fig. 1a in [1] ) to total KIT expression ( Fig. 1b in [1] ) indicates that KIT WT is expressed almost exclusively at the surface, while this is the case for 70% of KIT Ex9. This value drops to 50% for both Ex11 mutants. The results of the FACS analysis after SCF stimulation (Fig. 2) indicate the decrease of KIT expression at the cell surface for all KIT mutants and wild type following stimulation with KIT ligand, SCF. The Mean Fluorescence Intensity (MFI) of Kit staining in the different Kit mutants are indicated in Table 1 .
While PDGFRα, Akt, and Erk phosphorylation were induced by PDGFAA in PDGFRaWT, phosphorylation of PDGFRα, Akt, Erk and STAT5 remained identical to the non-stimulated control for the PDGFRA mutant V591D, as previously shown [3] . In contrast, Kit mutants exhibit all constitutive phosphorylation of kit at tyrosine 703 but the signal intensities for Erk, Akt and STAT5 phosphorylation was further increased upon SCF stimulation (Fig. 3a and Fig. 3b) .
STATs translocation to the nucleus was identified for Kit Ex11 deletion mutant and for Kit Ex9 duplication mutant to a lower extend. Induction of gene expression known to be part of the STAT pathway was found for Kit Ex11 deletion mutant after SCF stimulation as well as for Kit Ex9 duplication mutant upon SCF stimulation to a lower extend (Fig. 4a and Fig. 4b) .
We investigated KIT Ex11 specific gene signature, comparing KIT Exon 11 deletion mutant regulated genes to other GIST mutants (PDGFRA mutants and KIT Exon 9). 277 genes (Table 3) were differentially expressed in KIT Ex11 deletion mutant only. As noted in [1] , these genes were associated with "cell cycle" and "insulin signalling pathway".
Both inhibitors were added to the medium 24 h after seeding for 30 h. Both drugs were added individually and in combination with a constant ratio of 1:1 (Fig. 5) . Viability was assessed using PrestoBlue following the manufacturer's recommendation. Results were analysed using the Compusyn software [5] and the combination Index (CI) values are represented as a function of the percentage of inhibition. CI values below 1 indicates a synergy between the two compounds, while CI values above 1 indicates antagonism.
GIST882 were treated with 100 nM imatinib for different times and mRNA expression level of ETV4, ETV5, egr1, FosL2 and FosB were assessed by qPCR. n ¼ 3, Mean7 SEM (Fig. 6) .
qPCR primers are listed in Table 2 .
Experimental design, materials and methods

Flow cytometry analysis
Cell surface expression of KIT wild type and mutants was analyzed by flow cytometry using a FACS CantoII Instrument (Becton Dickinson, Heidelberg, Germany) either without ligand (blue lines) or 15 minutesmin after stimulation with 100ng/ml100 ng/ml SCF (pink lines). Cells were then either incubated with 10 μL KIT primary antibody (anti-CD117-APC conjugated; C7244; Dako, Belgium) for cell surface expression. Specificity was controlled using an isotype-matched/ APC conjugated antibody (grey). 
Western blot analysis
Cell lysis was performed on ice, using 1x Laemmli buffer. Proteins were subjected to SDS-PAGE, transferred to polyvinylidene difluoride membranes (Roth) and probed with primary antibodies. Primary antibodies against PLCγ and phosphospecific antibodies against STAT1 (pTyr701), STAT3 (pTyr705), ERK1/2 (pThr202/pTyr204), PDGFRA (pTyr849)/β(pTyr857), AKT (pSer473) and Mek1/2 were purchased from Cell Signalling Technology. Anti-STAT1 and anti-STAT3 antibodies and phosphospecific antibodies for STAT5 (pTyr694) and PLCγ1 (pTyr783) were obtained from BD Biosciences. Antibodies against STAT5 (C-17), PDGFRα (C-20), ERK1 (C-16), ERK2 (c-14), AKT1/2 (N-19) and tubulin (DM1A) were bought from Santa Cruz. Anti-CD117 (KIT) antibody was obtained from Dako and horseradish peroxidase-conjugated secondary antibodies from Cell Signalling Technology. Signals were detected on a Fusion-FX7 chemiluminescence detection device (Vilber) using a home-made ECL (Enhanced ChemiLuminescence) solution containing 2.5 mM luminol, 2.6 mM hydrogenperoxide, 100 mM Tris/HCl pH 8.8 and 0.2 mM para-coumaric acid [6] . Signal intensities were quantified using the Bio1D analysis package (Vilber).
Microarray analysis
293FR cells expressing KIT-WT, KIT Ex11 deletion mutant and KIT Ex9 mutant were incubated with 5 ng/ml doxycycline and 100 ng/ml SCF for 21 h in DMEM with 1%FCS. Cells were then starved for 3 h (without FCS) and further stimulated with SCF. RNAs of three biological replicates were isolated using the miRNeasy Mini KIT (Qiagen) according to manufacturer's instructions with additional on-column DNase I digestion. RNA quality and purity were assessed using a Nanodrop Spectrophotometer (Thermo Scientific) and Agilent 2100 Bioanalyzer (Nano KIT). Gene Expression analysis was performed using GeneChip Human Gene ST 2.0 arrays (Affymetrix). Quality control and data normalization were performed as previously reported [3, 7] . We focused on differentially expressed genes (DEG) across the mutants comparing with non-stimulated KIT-WT. To exclude non-relevant lowly expressed transcript clusters, only those showing log2 expression above 4.5 were kept for further analysis. Transcript clusters were further summarized in order to obtain a single expression value for each gene in each experiment. The differentially expressed genes were statistically evaluated by two-factor linear model with empirical Bayes statistics approach using limma package of R/Bioconductor [8] . In order to correct for the false discovery rate (FDR), the Benjamini and Hochberg step-up method correction was applied. Probe-sets with FDR o0.05 and absolute fold change 40.5 were considered to be significantly differentially expressed (DEGs). Microarray data are available in the ArrayExpress database (www.ebi.ac. uk/arrayexpress) under accession number E-MTAB-4548. KIT Ex11 specific gene signature was determined by comparing KIT Exon 11 deletion mutant regulated genes to other GIST mutants (PDGFRA mutants and KIT Exon 9). 277 genes.
Nuclear extract preparation
Nuclear extracts were prepared as previously done [4] . In brief, cells were washed with ice-cold PBS, harvested gently with cell scraper and centrifuged at 4°C for 5 min, 4000 rpm. The pellet was then resuspend in Buffer A (10 mM Hepes/KOH pH7.9, 1.5 mM MgCl2 and 10 mM KCl). Following 10 min incubation on ice, samples were centrifuged at maximum speed, 4°C for 5 min. The operation was performed a second time and the pellets were finally resuspended in Buffer C for nuclear extraction (20 mM Hepes/KOH pH7.9, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA and 25% glycerol). Protein concentrations were determined using Bradford reagent before analysis by western blotting.
Synergy analysis
Synergy between Receptor Tyrosine kinase (RTK) and MEK inhibitors were performed at constant ratio, as recommended by Chou et al. [5, 9] . GIST primary cells were seeded in 96 well plates 24 h prior ACER2  CCNYL1  EYA1  IRX4  LOC401321 NKX3-1  RN5S217  SNORA10  UTRN  ADAMTS20  CD109  FAHD1  ITGA2  LOC642838 NLRP1  RN5S335  SNORA16B  VRK3  ADCK3  CD3EAP  FAM46A  JAM2  LOC645166 NOA1  RND2  SNORA2A  WDR63  ADCY1  CD68  FAM47A  JMY  LPAL2  NR1D2  RNF167  SNORD111  WDR77  AKAP8  CDC25B  FAM59A  KCNA3  LPCAT2  NRN1  RNFT1  SNORD126  WWP2  ALDH1L2  CDT1  FAM64A  KDELR1  LPHN3  OLIG2  RNU2-7P  SNORD3C  ZC3H6  ALG12  CES3  FAM83B  KDELR3  LPPR4  PABPC1L  RNU7-6P  SNORD60  ZFP14  AMIGO2  CHEK2  FBXO32  KIAA0355  LRFN1  PAMR1  RPL13P5  SNORD71  ZNF140  ANKRD18DP  CITED1  FLJ44342  KIAA1430  LURAP1L  PAQR4  RYR2  SNORD91A  ZNF17  ANKRD20A12P CKMT1A  FLJ45248  KIAA1609  LYSMD2  PARK2  SAMD15  SRCRB4D  ZNF239  ANKRD20A5P  CNN2  FRAT2  KLF11  MALAT1  PARM1  SCARA5  TAS2R31  ZNF280B  ANKRD27  CNTNAP3B GALNT6  KLHL24  MCL1  PARP14  SCARNA21 TBX15  ZNF296  ARHGAP20  CPEB4  GGA2  KLHL36  MCM5  PARP4  SEMA6A  TCF25  ZNF347  ARHGAP35  CPPED1  GLTSCR2  KLRAP1  MDM2  PBX1  SERPINB1 TFAP4  ZNF485  ARHGEF1  CRKL  GRAMD4  LCMT1  MED12L  PCDH7  SGK1  THOC6  ZNF502  ARNT2  CRYBB2P1 GSPT2  LIG4  MGARP  PDP1  SGSM3  TIGD4  ZNF574  ASRGL1  CSDA  GYPC  LIN37  MGST1  PDPR  SHKBP1  TMEM143  ZNF581  BACE1-AS  CYP2S1  GYS1  LINC00282  MIR22HG  PHKB  SHMT2  TMEM159  ZNF70  BBIP1  CYP4 Â 1  H2BFXP  LNP1  MIR3143  PKIA  SLC35B2  TMEM185B  ZNF738  BCL6  DDTL  HIST1H2BG LOC100130776 MIR338  PLA2G7  SLC44A2  TMEM238  ZNF836  BEX5  DEDD2  HIST1H3A  LOC100132439 MIR3671  PLXNA2  SLC45A3  TNFRSF10D  ZSCAN12P1  BRD2-IT1  DLC1  HIST1H3H  LOC100133985 MIR4263  PMFBP1  SLC6A6  TNFRSF13C  BZW1  DMRTA1  HLA-DRB5 LOC100272228 MIR4324  PPP1R13L SLC7A6OS TNRC6B  C10orf10  DYNLL2  HSDL1  LOC100287628 MIR4530  PPP1R14C SLC8A1  TOM1  C10orf25  EBF3  IER5  LOC100288018 MIR4773-2 PROX1  SLC9A1  TP53I13  C19orf54  ECH1  IFITM3  LOC100288520 MIR548A2 PRPH  SLC9A2  TRBV23OR9-2  C22orf13  EID3  IGHD2-21  LOC100507299 MRI1  PRR12  SLC9A9  TRBV6-9  C2orf77  EIF1  IL11  LOC147670  MTRF1L  PSEN2  SMOC1  TRPC1  CABIN1  ELAC1  ILDR2  LOC147727  MTSS1  RAB39B  SMPD1  TRPS1  CABLES1  EMR2  IMPA2  LOC284648  NFIX  RBL2  SNAR-D  TSC2  CAMLG  EPHX4  INPP5D  LOC399815  NIPSNAP1  RHBDF1  SNAR-H  TSSK3  CAP2  EPS15L1  IQCH  LOC400927  NIPSNAP3A RN5S180 SNN  TXNDC17 treatement. Inhibitors were added at concentration between 5 nM and 13 μM, either alone or in combination to a final volume of 90 μL. Endpoint viability was assessed using PrestoBlue (Thermofischer), by adding 10 μL of reagent to each well. Following 30 min incubation, fluorescence intensities were recorded on a CLARIOstar microplate reader (BMG LABTECH). Inhibition was then calculated as a ratio to the non-treated samples.
